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Objective: We sought to evaluate treatment response to a novel combined-modality
treatment regimen for localized esophageal carcinoma.
Methods: Localized esophageal carcinoma was confirmed with endoscopic ultra-
sonography, computed tomography, and positron emission tomography before in-
duction therapy. This therapy consisted of combined cisplatin/paclitaxel (cisplatin,
75 mg/m2; paclitaxel, 175 mg/m2; 2 cycles, 3-hour infusion) for weeks 1 and 4,
combined cisplatin (30 mg  m2  wk1) and paclitaxel (30-80 mg  m2  wk1,
96-hour infusion) with concurrent radiation (external beam, 1.8 Gy/d; total, 50.4
Gy) for weeks 7 to 12, and esophagectomy for week 16 after restaging confirmed
resectability.
Results: Forty-one patients (36 men) with adenocarcinoma (n  25) or squamous
cell carcinoma (n  16) were enrolled. Thirty-six patients completed treatment, of
whom 34 (85%) had locally advanced disease of clinical stage T3-4 N0-1. Symp-
toms resolved or improved in 35 (92%) of 38 patients after induction chemotherapy.
Fourteen (35%) and 10 (24%) patients experienced grade III/IV myelosuppression
during induction chemotherapy and chemoradiation, respectively. Two (5%) had
grade III and none had grade IV esophagitis during chemoradiation. Only 2 (5%)
patients required enteral feeding-tube support during therapy. Of 33 R0 resections,
9 (26%) had complete pathologic disease, and 4 (12%) had microscopic residual
disease. Major (eg, anastomotic response, delayed stricture, and respiratory failure)
postoperative morbidity occurred in 13 (36%) of 36 patients. Operative mortality
was 5.5% (2/36).
Conclusion: This regimen of induction concurrent chemoradiation followed by
surgical intervention for esophageal carcinoma produces rapid dysphagia relief with
initial chemotherapy, has a high overall response rate, and has acceptable toxicity
levels.
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The incidence of esophageal carcinoma, par-ticularly, adenocarcinoma, is rapidly in-creasing in the United States. Although ear-ly-stage esophageal carcinoma is highlycurable, the overall survival of patients withesophageal carcinoma is dismal because
most patients present with advanced disease.1 In the year
2000, 12,300 patients were diagnosed with esophageal can-
cer, and an estimated 12,100 died of disease.2 Single-mo-
dality therapy in the form of surgical intervention or radia-
tion therapy for locally advanced cancers has achieved little
improvement on the 20% 5-year survival for stage III
esophageal carcinoma. The failure of surgical or radiation-
based treatment to cure most patients with esophageal can-
cer is attributable to the high incidence of both extensive
locoregional and systemic disease at the time of diagnosis.
Such disappointing treatment outcomes have led investiga-
tors to examine the role of multimodality therapy.
Prospective trials comparing preoperative or postopera-
tive radiation or chemotherapy alone with surgical interven-
tion alone have found no improvement in survival with
either adjuvant treatment modality.3-5 Randomized clinical
trials have shown a survival advantage for concurrent che-
moradiation therapy over that of radiation alone for locally
advanced esophageal cancer.6,7 A prospective randomized
controlled trial demonstrated a survival benefit for com-
bined 5-fluorouracil (5-FU)/cisplatin, radiation, and surgical
intervention compared with surgical intervention alone for
patients with esophageal adenocarcinoma.8 The improve-
ment in survival was modest (16 vs 11 months), however,
and the toxicity of treatment was significant.
In a multicenter phase II trial of paclitaxel, cisplatin, and
5-FU, we identified significant antitumor activity of the
combination of agents in advanced esophageal carcinoma,
but the associated toxicity was substantial.9 Similar re-
sponse rates were seen with paclitaxel and cisplatin, with
significantly less treatment-related toxicity without the ad-
dition of 5-FU. In a second phase II trial, we identified a
major treatment response in 38% of patients with locally
advanced esophageal cancer treated with preoperative pac-
litaxel and cisplatin.10 There were no complete pathologic
responses observed. Despite tumor downstaging, the rate of
complete resection (62%) after induction chemotherapy was
no different than that with surgical intervention alone at our
institution.
On the basis of the high rate of antitumor activity and
improved toxicity profile of induction paclitaxel/cisplatin
but because of its failure to improve on curative rates of
resection, we added concurrent chemoradiation therapy af-
ter induction chemotherapy as part of a combined-modality
preoperative treatment approach to localized esophageal
cancer. The objectives of this trial were to determine the
feasibility of this combined-modality regimen and to assess
the pathologic complete response rate after induction ther-
apy.
Patients and Methods
We conducted a phase I/II study of preoperative combined-modal-
ity therapy for localized esophageal carcinoma consisting of pac-
litaxel/cisplatin followed by radiation therapy concurrent with
paclitaxel/cisplatin before esophagectomy. Chemotherapy dose es-
calation was made on the basis of a tandem nonsurgical phase I
trial identifying the tolerable dose of paclitaxel. The primary end
point of the phase II study was the feasibility of this combined-
modality regimen. Secondary end points included complete patho-
logic response to preoperative therapy, relief of dysphagia, treat-
ment-related toxicity, and surgical morbidity and mortality.
Eligibility Criteria
Patients were eligible if they were 18 years of age or older and had
histologically confirmed, surgically resectable (T2-4 N0-1 M0)
adenocarcinoma or squamous cell carcinoma of the middle and
distal esophagus. Patients who had T1 tumors were eligible if they
had involved regional lymph nodes. The T and N stage were
defined by means of endoscopic ultrasonography. Tumors that
extended into the proximal stomach had to be located predomi-
nantly in the distal esophagus or gastroesophageal junction to be
eligible. Additional eligibility criteria included a performance sta-
tus of 70% or greater (Karnofsky scale) and adequate pulmonary
(forced expiratory volume at 1 second 1.2 L) and organ function
(absolute granulocytes 1500/mm3, platelets 150,000/mm3, se-
rum creatinine 1.5 mg/dL, serum calcium 12 mg/dL, and
serum bilirubin 1.5 mg/dL). Patients with prior malignancies
were eligible if they were disease free for over 5 years.
Exclusion Criteria
Patients were ineligible if they had another active malignancy, had
a cervical esophageal cancer, had Tis or T1 N0 tumors or M1a or
M1b disease, or could not tolerate the planned combined-modality
treatment medically.
Pretreatment Evaluation
The pretreatment evaluation included history, physical examina-
tion, electrocardiography, pulmonary function testing, and labora-
tory testing. The extent of disease evaluation included chest radi-
ography, esophagogastroduodenoscopy, barium esophagography,
computed tomography of the chest, endoscopic esophageal ultra-
sonography, and positron emission tomography. Pretreatment
bronchoscopy was performed for midesophageal tumors. Laparo-
scopic staging was performed for patients with distal esophageal or
gastroesophageal junction adenocarcinomas at the discretion of the
treating surgeon. The clinical TNM status and tumor stage were
defined according to the 1997 guidelines of the American Joint
Committee on Cancer Staging.11
Dysphagia was assessed according to a 5-tier dysphagia scale,
in which a score of 0 corresponded to tolerance of normal diet, a
score of 1 corresponded to some solid food, 2 corresponded to
semisolid food only, 3 corresponded to liquids only, and 4 corre-
sponded to complete inability to swallow. Quality-of-life assess-
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ments were made according to the EORTCCQLQ-C30 and
FACT-G (version 2) questionnaire.
Induction Chemotherapy
The treatment plan is shown in Figure 1. It was administered as
outpatient therapy starting with paclitaxel/cisplatin once every 3
weeks for 2 cycles (weeks 1 and 4), followed by paclitaxel/
cisplatin weekly for 6 weeks with concurrent radiation. Paclitaxel
was given by means of 3-hour infusion on day 1 at a dose of 175
mg/m2, followed by cisplatin on the same day administered by
means of bolus injection at a dose of 75 mg/m2 through a central
venous catheter. During radiation, cisplatin was given at a fixed
dose of 30 mg/m2 by means of bolus injection, and paclitaxel was
administered at doses of 30 to 80 mg/m2 by means of 96-hour
infusion once weekly (total of 6 cycles; days 1, 8, 15, 22, and 29).
Standard antiemetic therapy was used. The dose escalation of
paclitaxel during radiation was based on a nonsurgical phase I trial
of paclitaxel, cisplatin, and radiation being conducted in parallel
with this preoperative trial. Dose attenuation was made for cisplatin-
associated grade III or IV ototoxicity, renal toxicity, and neuro-
toxicity; mucositis; nausea/vomiting/diarrhea/dehydration (grade
III or IV) and fatigue (grade IV only); and paclitaxel-associated
hematologic toxicity.
Induction Radiation
Multifield, external-beam megavoltage radiation was delivered by
using high-energy linear accelerators (10 MeV). Patients were
treated 5 days per week at 1.8 Gy per day administered over a
6-week period (weeks 7-12). Total dose of radiation was 50.4 Gy.
All fields were treated each day. Treatment was given with a
combination of anterior-posterior, oblique, or lateral fields, such
that the dose to the target volume did not differ from the dose
specified at isocenter by greater than 10%. The administered dose
was prescribed to the isodense line covering the volume at risk.
The superior and inferior borders of the radiation field were 5
cm and the anterior, posterior, and lateral borders were 2 cm
beyond the primary tumor, as defined by barium esophagography,
computed tomography, or esophageal ultrasonography (whichever
was larger). The primary tumor and locoregional lymph nodes
were included. If treatment-related toxicity necessitated a delay in
treatment exceeding 2 weeks, the patient was removed from the
study.
Evaluation During the Study
Patient evaluation during induction chemotherapy and concurrent
chemoradiation therapy included interim history and physical ex-
amination, performance status and weight measurement, and lab-
oratory testing. After induction chemotherapy was completed,
esophagogastroduodenoscopy, barium esophagraphy, and com-
puted tomography of the chest were performed.
Surgical Resection
Esophageal resection was performed 4 to 8 weeks after completion
of induction chemoradiation. Acceptable approaches to resection
included the Ivor-Lewis esophagogastrectomy, subtotal thoracic
esophagectomy through a left thoracoabdominal approach or com-
plete thoracic esophagectomy through a right thoracotomy, lapa-
rotomy, and cervical esophagogastric anastomosis (McKeown ap-
proach). Transhiatal esophagectomy with cervical anastomosis
was acceptable for tumors at or inferior to the pulmonary vein.
Radical en bloc esophagectomy that includes resection of adjacent
pericardium, pleura, diaphragm, azygos vein, and thoracic duct
and extensive mediastinal, celiac, and retroperitoneal lymphade-
nectomy were not performed. Frozen sections were obtained to
ensure microscopically negative proximal and distal margins.
Mediastinal lymphadenectomy was performed en bloc with
resection of the primary tumor when possible. When feasible,
lymph node dissection included all lymphatic tissue between the
Figure 1. Treatment plan for patients with esophageal carcinoma receiving induction chemotherapy and radiation.
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tracheal bifurcation and the celiac axis, including common hepatic,
celiac, and splenic nodal tissue. Bilateral cervical lymphadenec-
tomy (extended lymphadenectomy) was not performed. At a min-
imum, mediastinal lymph nodes and fat 5 cm proximal and distal
to the primary tumor were excised en bloc during esophagectomy.
Either the handsewn or stapled anastomotic technique was permis-
sible and was left to the discretion of the operating surgeon.
Criteria for Response and Toxicity
Complete pathologic response was defined as the absence of viable
tumor in the resected primary tumor or regional lymph nodes.
Progressive disease was evident when an increase in tumor volume
exceeded 25% or an unequivocal new lesion or lesions appeared.
All toxicities encountered during this study were reported accord-
ing to the National Cancer Institute Common Toxicity Criteria.
Radiation morbidity was scored according to the RTOG Acute
Radiation Morbidity Scoring Criteria (0-4).
Surgical complications were identified during treatment but
were also scored retrospectively according to a 5-tier surgical
morbidity and mortality scale recently developed at Memorial
Sloan-Kettering Cancer Center by using predefined criteria for
surgical secondary events. Grade I morbidity is that requiring only
oral medications for relief of signs or symptoms (eg, oral antimi-
crobial therapy for wound cellulitis). Grade II morbidity requires
intravenous pharmacotherapy or nutrition for significant symptoms
(eg, intravenous antiarrhythmic therapy for supraventricular tachy-
cardia). A grade III complication is one that requires endoscopy,
interventional radiology, or reoperation (eg, operative drainage of
an abscess that follows an anastomotic leak). Grade IV morbidity
is one that has attendant chronic disability (eg, postoperative
respiratory failure resulting in pulmonary fibrosis and reduction in
performance status) or requires major organ resection. The grade V
category refers to death associated with the sequelae of the peri-
operative complication.
Postoperative Follow-up
Patients were evaluated every 3 months for the first 2 years after
treatment, every 6 months for the next 3 years, and then annually.
Surveillance included interim history and physical examination,
performance status and weight measurement, and laboratory test-
ing. Esophagogastroduodenoscopy and computed tomography of
the chest and abdomen were performed every 6 months for 2 years
and annually thereafter.
Results
Clinical and Pathologic Characteristics
Forty-one patients, of which 36 (88%) were men, were
entered into the study (Table 1). The median patient age was
59 years (range, 37-77 years). Ninety-three percent (n 38)
of patients had dysphagia as part of the presenting symp-
tomatology. Twelve (29%) patients experienced weight loss
exceeding 10% of their premorbid body weight. The median
patient performance status was 90% (range, 80%-100%).
The majority of cancers involved the distal esophagus (n 
29 [71%]). Over eighty-five percent of patients initially
presented with locally advanced transmural disease (T3-4
N0-1, n  34 [83%]). Twenty-five (61%) tumors were
adenocarcinomas, and the remainder were squamous cell
cancers.
Dysphagia Relief With Induction Chemotherapy and
Chemoradiation
Thirty-eight patients had pretreatment dysphagia. This re-
solved or improved in 35 (92%), worsened in 1 (3%), and
was unchanged in 2 (5%) after induction chemotherapy.
Two of the 41 (5%) enrolled study patients had grade III or
IV esophagitis during concurrent chemoradiation. Only 2
(5%) patients required enteral feeding-tube support during
therapy.
Treatment-related Toxicity and Complications
The median pretreatment and posttreatment performance
status was 90% (range, 70%-100%). The lowest median
performance status observed during induction therapy was
70% (range, 60%-90%). One patient with a history of pe-
ripheral vascular disease had a cerebrovascular accident
during treatment that resulted in prolonged treatment delay
and removal from the study. One patient died during treat-
ment after a traumatic hip fracture that was complicated by
acute respiratory failure. In a third patient brain metastasis
was diagnosed by means of brain biopsy after chemoradia-
tion. Two patients were found to have metastatic disease at
the time of the operation (pleural and omental metastases)
and did not undergo resection. One patient experienced lung
metastasis during chemoradiation and underwent palliative
esophageal tumor resection.
The most commonly encountered significant treatment-
related toxicity was myelosuppression. Toxicity was not
TABLE 1. Pretreatment patient and tumor characteristics
Characteristic n % of total
No. of patients 41
Male/female 36:5
Median age, y (range) 59 (35-77)
Dysphagia 38 93
Weight loss 10% premorbid weight 12 29
Karnofsky performance status
80% 5 12
90% 36 88
Site
Midesophagus 12 29
Distal esophagus 29 71
Gastroesophageal junction 17
Histology
Adenocarcinoma 25 61
Squamous cell carcinoma 16 39
Initial clinical stage
IIA 9 22
IIB 5 12
III 24 59
IV 1 2
Tx Nx/T3 Nx 2 5
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dose related. Fourteen (35%) patients experienced grade III
or IV neutropenia during induction chemotherapy. Ten
(24%) patients had grade III or IV neutropenia, and 13 had
grade III anemia during chemoradiation. Six (15%) patients
had treatment delays, and 10 (24%) patients were hospital-
ized for treatment-related toxicity.
Significant nonhematologic toxicity was infrequent and
limited to nausea and vomiting of grade III or IV in 3 (14%)
patients. Two patients had grade III and none had grade IV
esophagitis during chemoradiation. Four patients required
endoscopic esophageal dilatation during preoperative treat-
ment for tumor-related stricture. One patient was dilated on
2 separate occasions, each complicated by esophageal per-
foration that was successfully managed with nonoperative
therapy. Seven (17%) other patients required intravenous
fluids, and 5 of these experienced treatment delays. Diarrhea
and constipation were all grades I or II in severity. No
patient experienced grade III or IV stomatitis, and only 2
(5%) had grade III neurotoxicity. No patient had grade III or
IV nephrotoxicity.
Clinical Response to Induction Therapy
Response to therapy is outlined in Table 2. Thirty-six
(87.8%) of 41 patients completed the preoperative treatment
regimen. Four (10%) patients had disease progression, and
2 (5%) did not complete treatment because one died after a
hip fracture and one had a stroke during neoadjuvant ther-
apy.
Surgical Intervention and Operative Morbidity and
Mortality
Thirty-six patients have completed the entire treatment pro-
tocol and are evaluable for response. The operative mortal-
ity rate was 5.5% (2/36). The majority of patients (78%
[28/36]) underwent an Ivor Lewis esophagogastrectomy.
Five (14%) and 3 (8%) patients underwent a McKeown
approach and a transhiatal esophagectomy, respectively.
Thirty-three (92%) of 36 patients had R0 resections. Two
(5%) patients had palliative esophagectomy. The median
number of lymph nodes resected en bloc with the tumor-
containing esophagus for transhiatal esophagectomy,
McKeown approach, and Ivor Lewis esophagectomy was
16 (range, 14-23), 13 (range, 11-32), and 17 (range, 4-40),
respectively.
Two (5.5%) patients had grade I and 13 (36.1%) had
grade II complications (Table 3). Over half of the grade II
morbidity represented postoperative, hemodynamically sta-
ble supraventricular tachycardia that rapidly resolved in all
cases with intravenous antiarrhythmic therapy. There were
5 anastomotic leaks that were managed without reoperation.
Seven (19%) patients had anastomotic leaks (2 handsewn
and 5 stapled anastomoses). Two patients required reopera-
tion for anastomotic dehiscence, and the remaining leaks
were managed nonsurgically. There were no instances of
recurrent laryngeal nerve injury or chylothorax.
Three (8.3%) patients had grade IV morbidity character-
ized by chronic disability or organ dysfunction after sepsis
(ie, acute renal and respiratory failure during a prolonged
intensive care unit course in all 3 patients, one of whom
later died). In 2 of these patients, the sepsis was precipitated
by anastomotic leak and in one patient by nosocomial
pneumonia. One patient required reoperation after the anas-
tomotic disruption, and another required tracheostomy for
chronic ventilator dependence. The other death or grade V
complication occurred in a patient who experienced massive
intrathoracic hemorrhage of unknown cause 1 week after
resection that could not be controlled at reoperation.
Pathologic Findings After Clinical Staging
Nine (22% of all resections and 26% of R0 resections)
patients had no evidence of carcinoma in the resected spec-
imen, and 4 had microscopic residual disease. Five (31%) of
16 patients with squamous cell carcinoma and 4 (22%) of 25
patients with adenocarcinoma had complete pathologic re-
sponse to treatment. All complete pathologic responses
TABLE 2. Results of treatment with combined modality
therapy for localized esophageal carcinoma (n  41)
Characteristic n % of total
Completed treatment 36 88
R0 resection 33/36 92
R1 resection 2/36 5
pCR 9/36 22
Microscopic residual disease 4/41 10
pCR adenocarcinoma/squamous cell cancer 4/5 16/31
pCR (paclitaxel 40-80 mg/m2) 9/25 36
pCR adenocarcinoma/squamous cell cancer
(paclitaxel 40-80 mg/m2)
9/25 36
Downstaged 25/41 60
No change 8/41 20
Stage increased 6/41 15
Four patients had disease progression during induction therapy, and 2
went off study because of treatment delays unrelated to toxicity.
pCR, Complete pathologic response.
TABLE 3. Operative complications (n  36)
Grade n % of total
I 2 5
II 13 36
III 10 28
IV 3 8
V 2 5
Grade I, Supportive or bedside care, oral antibiotics, etc; Grade II, intra-
venous fluids or medications, parenteral or enteral nutrition, etc; Grade III,
interventional radiology, endoscopy, or operative intervention required;
Grade IV, chronic disability, major organ resection or intensive medical
therapy; Grade V, death associated with sequelae of the event.
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were observed in patients receiving 40 to 80 mg/m2 pacli-
taxel (n  25). Thus 36% (9/25) of patients receiving 40 to
80 mg/m2 had a complete pathologic response. Twenty-five
(60%) patients responded to preoperative treatments and
were downstaged. Eight (20%) failed to respond to treat-
ment, and the tumor stage increased in 6 (15%) during
treatment.
Discussion
In an effort to identify novel combined-modality treatment
regimens that are both potentially more effective and less
toxic than cisplatin/5-FU, we conducted a phase II trial of a
novel induction chemoradiation regimen for localized
esophageal carcinoma. The treatment regimen consisted of
preoperative combined paclitaxel/cisplatin induction che-
motherapy, followed by radiation with concurrent paclitax-
el/cisplatin. There are 3 notable findings in this study. First,
dysphagia resolved or improved rapidly in the majority of
patients (92%), with induction chemotherapy obviating the
need for nutritional support. Second, the gastrointestinal
toxicity was markedly less than that reported previously
with 5-FU–based regimens because only 2 (4.9%) patients
in this trial required enteral feeding tubes during chemora-
diation therapy. Myelosuppression was the most common
significant treatment-related toxicity. Finally, response rates
with the present multimodality regimen are at least compa-
rable with those reported for cisplatin/5-FU–based thera-
pies. Complete (R0) resection was possible in 33 (92%) of
36 patients who underwent surgical intervention. Postoper-
ative morbidity and mortality was similar or even lower
than what has been reported in previous combined modality
studies. The complete pathologic response rate of 22% also
compares favorably with those of other previously reported
studies.
Because of poor survival with surgical intervention alone
for locally advanced esophageal cancer, induction chemo-
therapy was introduced to increase the likelihood of eradi-
cating locoregional and distant micrometastatic disease and
downstaging the primary tumor. These studies have failed
to show an overall survival benefit with preoperative che-
motherapy versus that with surgical intervention alone.5,12
Resectability rates were significantly higher with induction
therapy (67% vs 35%), yet complete response rates were
only 7%.11 More than half of the patients did not benefit
from chemotherapy before the operation but were exposed
to treatment-related toxicity.
Low complete response rates to preoperative chemother-
apy alone prompted investigators to evaluate neoadjuvant
chemoradiation. Of 5 randomized trials that have compared
induction chemoradiation therapy with surgical intervention
alone, only one has demonstrated a significant survival
advantage for multimodality treatment.8,13-16 These trials
used preoperative platinum-based regimens with 5-FU or
bleomycin, and radiation doses ranged from 20 to 50 Gy.
Complete pathologic response rates were less than 27%.
Operative mortality rates were significantly higher with
combined-modality therapy (8.5%-24% vs 3.6%-13%). The
trial reported by Walsh and colleagues8 demonstrated a
significant survival advantage for multimodality therapy
(32% vs 6%, 3-year survival). It is unclear whether patients
in the 2 treatment arms were identically staged; short fol-
low-up, selection bias, high operative mortality, and an
unusually poor survival in the surgical intervention-only
control arm confound the findings of this trial. Although the
results of nonrandomized and randomized trials of com-
bined-modality therapy are conflicting and not fully com-
parable because of differences in eligibility criteria and
treatment regimens, no sustained benefit has been shown for
combined-modality therapy, making it imperative to de-
velop novel treatment regimens.
Cisplatin/5-FU–based multimodality regimens are also
associated with significant gastrointestinal toxicity. Foras-
tiere and associates17 reported severe esophagitis in 86% of
patients treated with concurrent cisplatin, 5-FU, vinblastine,
and radiotherapy before esophagectomy; 79% of these pa-
tients required nutritional support. On the basis of these
data, recent trials of cisplatin/5-FU–containing multimodal-
ity regimens have required placement of feeding enterosto-
mies in all participating patients before treatment.18 The
lack of clear efficacy of cisplatin/5-FU regimens and their
associated toxicity have led many investigators to look for
alternatives to 5-FU–based chemotherapy as an induction
therapy agent.19-22
Antitumor synergy and nonoverlapping toxicity make
combined paclitaxel/cisplatin an attractive alternative to tra-
ditional cisplatin/5-FU therapy. Our results demonstrate that
initial therapy with paclitaxel and cisplatin is very effective
in providing relief of dysphagia, thereby facilitating rapid
resumption of oral intake. The incidence of grade III or IV
esophagitis during chemoradiation is low (5%), and only
5% of our patients required enteral nutritional support
through a feeding tube. No patient required other invasive
palliative measures (eg, stents or laser ablation).
Major operative morbidity and mortality rates with this
multimodality regimen for esophageal cancer are similar to
those reported in other trials of trimodality therapy.8,13-16
The toxicity profile of this preoperative induction cisplatin
and paclitaxel chemotherapy followed by concurrent che-
moradiation is more favorable than that of cisplatin/5-FU
and suggests that omitting 5-FU ameliorates toxicity with-
out compromising treatment response. The rate of complete
pathologic response with the multimodality treatment used
in this study is similar to that seen in other trials and leaves
room for improvement. Therefore we continue to test other
novel induction therapy regimens, including the addition of
targeted therapies to standard chemotherapy, to determine
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whether we can increase the complete pathologic response
rate further.
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Discussion
Dr Richard F. Heitmiller (Reisterstown, Md). I appreciate the
opportunity to review and discuss this article by Dr Stojadinovic
and colleagues from the Memorial Sloan-Kettering Hospital in
New York, who have long been leaders in the treatment of patients
with esophageal cancer.
In this study Dr Stojadinovic and colleagues describe a phase II
trial that uses induction chemotherapy before concurrent chemo-
radiation therapy, followed by surgical intervention. In our expe-
rience at Johns Hopkins, trials with chemoradiation therapy fol-
lowed by surgical intervention have demonstrated excellent local
control of tumor. In other words, the pattern of treatment failure is
predominantly systemically with distant metastatic disease. At-
tempts to increase the systemic component of therapy before or
after surgical intervention have been limited by toxicity, poor
compliance, and lack of measurable benefit. The treatment proto-
col used by Dr Stojadinovic and colleagues is a very intriguing
way to increase the total chemotherapy dosage, thereby intensify-
ing the systemic component of therapy in a neoadjuvant manner,
which appears to improve patient tolerance and toxicity. Further-
more, the authors select cisplatin/paclitaxel instead of cisplatin/
5-FU to minimize the risk of gastrointestinal toxicity.
The authors are to be congratulated on their efforts using this
very aggressive therapy. However, I am sure that even they are
disappointed by the lack of improvement in complete response
rates and survival compared with that seen in other neoadjuvant
series in which induction chemotherapy was not used.
For comparison, I cite the results from our most recent pub-
lished series, which appeared in the Journal of Clinical Oncology
(J Clin Oncol. 2000;18:868-76). In this trial cisplatin/5-FU and
radiation followed by surgical intervention were administered in
42 patients with esophageal cancer compared with the 41 patients
from this particular series. The 2 series are roughly concurrent.
Outcome results are presented for this study followed by our
results, respectively, for each of the following parameters: grade
3/4 myelosuppression, 59% and 52%; grade 3/4 esophagitis, 19%
and 14%; enteral tube feeding, 4.9% and 21%; successful comple-
tion of therapy, 88% and 93%; R0 resection, 94% and 83%;
surgical complications, 36% and 37%; and anastomotic leak, 19%
and 2.4%. The complete response rate is approximately the same,
22% and 26%, and 2-year survival is 62% in both series, although
their reported survival is disease specific and ours is overall.
The authors conclude that induction chemotherapy improves
the symptom of dysphagia in 92% of patients, which obviates the
need for enteral feeding supplementation. Clearly their enteral
feeding rate is lower than ours. The authors seem to believe that
enteral feeding is a liability. We do not. It is our belief that strictly
maintaining nutritional status during therapy is essential to a
successful treatment outcome. Therefore, our policy has been to
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place jejunostomy tubes at the time of pretreatment laparoscopic
staging and to use these liberally during therapy.
The authors conclude that their protocol has less gastrointesti-
nal toxicity than those such as ours using cisplatin/5-FU. This was
true in our initial experience, but now our incidence of gastroin-
testinal toxicity is the same as they report.
Finally, the authors conclude that complete response rates and
survivals are comparable with those of series using cisplatin and
5-FU. This is certainly true, although their treatment requires more
time and is associated with greater anastomotic complications.
I have the following questions. What are the real or theoretical
disadvantages of supplemental enteral feedings? Again, I think we
have a difference in our position on that. Why was there such a
high incidence of major complications and anastomotic dehis-
cences in particular? The third question, which I think you have
answered, is, “What is the pattern of tumor recurrence?” Finally,
how will these results influence the treatment plans at Memorial
Sloan-Kettering in the future?
Dr Jack A. Roth (Houston, Tex). The authors are to be
congratulated for the presentation of this novel strategy for treating
locally advanced esophageal cancer. We have treated approxi-
mately 100 patients at the M.D. Anderson Cancer Center using this
strategy, and credit for its development should go to Dr Jaffer
Ajani, a medical oncologist at M.D. Anderson, who proposed this
strategy 6 years ago. The results of the first 38 patients treated at
our institution will be presented at the Western Thoracic meeting
by Dr Stephen Swisher.
One of the differences between your series and ours is the
percentage of patients free of cancer, which, if calculated on the
basis of intention to treat, in your series is 15 of 42 patients, or
36%. This contrasts with the 26 of 38 patients, or 68%, free of
cancer with a median length of follow-up of 40 months in the M.D.
Anderson series, which is twice the length of follow-up in your
report. Why do these results differ?
5-FU used with cisplatin and taxol in the induction phase and
with cisplatin in the concurrent chemoradiation phase in the M.D.
Anderson Cancer Center series is not included in your regimen.
5-FU might be a critical drug in the chemotherapy regimen, as
suggested by its important role in the adjuvant chemotherapy
gastric cancer studies. Also, taxol was used during radiation in
your study, and this has been reported to increase toxicity but not
efficacy.
In our study severe neutropenia occurred in 25% of patients
compared with grade 3 and 4 toxicities of over 45% in your series.
I wonder if you could comment on dose reductions in chemother-
apy that might have been detrimental to efficacy.
This strategy appears to improve outcome in patients with
cancer of the esophagus without undue toxicity, and I think it
merits phase III intergroup trials, which are now under discussion.
Your study represents an important contribution in this area.
Dr Bains. I thank you for your comments and questions.
The first question posed by Dr Heitmiller regards our estima-
tion of enteral feedings in terms of whether it is a disadvantage or
a liability as stated. The purpose for emphasizing this point was not
to say that it is not important to nutritionally support the patient but
rather to say that we have tried to achieve an induction regimen
that lowers the rate of esophagitis and the need for enteral feeding-
tube placement to support nutrition because the patients cannot
sustain it on their own.
The second question relates to the high incidence of anasto-
motic problems. We tried to be very critical and forthcoming in
terms of defining the major operative morbidity in terms of anas-
tomotic complications. Clearly there was a majority of patients
with distal esophageal tumors, and those are the ones that experi-
enced the anastomotic leaks, 7 in total of the 36 that underwent
resection. This has caused us to critically review our radiation
fields and to determine what the exposure of the greater curvature
of the stomach was in induction therapy. We have reviewed and
cannot show at this point the literature that addresses this question
in specific and find that the morbidity and mortality rates of this
particular regimen are coincident with those reported over the last
17 years using trimodality therapy.
The other question was how does this influence our future
treatment. What we have done is we have omitted the induction
taxol and cisplatin and rely on concurrent cisplatin/taxol and
radiation as induction therapy and used the first 2 doses selectively
in the face of dysphagia. We have chosen the 3-hour infusion in
this study to try to limit the need for granulocyte colony stimulat-
ing factor support and myelosuppression and have selected as part
of concurrent chemoradiation the 96-hour infusion in an attempt to
optimize radiosensitivity and yet limit peak drug doses and attend-
ant toxicity. Other phase I trials that we are launching include
novel approaches that involve paclitaxel/cisplatin and CPT-11,
tyrosine kinase inhibitors, and antiangiogenesis agents. We are
formulating a trial now that will directly compare 96-hour infusion
of paclitaxel/cisplatin and radiation with induction 5-FU/paclitax-
el/cisplatin and 5-FU/cisplatin and radiotherapy.
The last question refers to why our results differ with regard to
5-FU. I think that the complete response rates, although clearly
suboptimal to what we would hope for, are no different; the
toxicity, we would say, is less than that with regard to the gastro-
intestinal toxicity, and the myelosuppressive effects have been
comparable. Have we considered a dose reduction with paclitaxel?
Yes, and that has been part of our planning for subsequent trials.
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